2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow NX-13: new trials by email Literature Review of NX-13 trials Research Report on NX-13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis | Phase 2 | Terminated | AbbVie | 81 | 2023-04-24 | 2026-06-15 |
| Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR - Ulcerative Colitis | Phase 1 | Completed | Landos Biopharma Inc. | 39 | 2021-05-05 | 2023-02-15 |
| Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers NX-13 250 mg, Placebo - Ulcerative Colitis | Phase 1 | Completed | Landos Biopharma Inc. | 56 | 2020-07-10 | 2022-03-10 |
Colitis, Ulcerative (3) · Lymphoma, Follicular (1)
Landos Biopharma Inc. (2) · AbbVie (1)
United States (2) · Australia (1) · Belgium (1) · Italy (1) · Poland (1) · Ukraine (1)